Evidence map›Paper›PMID 27974694›Full record

ArticleOncotarget2017

Hormophysa triquerta polyphenol, an elixir that deters CXCR4- and COX2-dependent dissemination destiny of treatment-resistant pancreatic cancer cells.

Sheeja Aravindan, Satishkumar Ramraj, Kathiresan Kandasamy, Somasundaram S Thirugnanasambandan, Dinesh Babu Somasundaram, Terence S Herman, Natarajan Aravindan

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Histidine Phosphorylation: Protein Kinases and Phosphatases.International journal of molecular sciences · 2024
    Review
  2. CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment.Journal of cancer research and clinical oncology · 2023
    Review
  3. Article
  4. Review
  5. Review
  6. Polyphenols as Possible Agents for Pancreatic Diseases.Antioxidants (Basel, Switzerland) · 2020
    Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Sheeja AravindanDepartment of Marine Sciences, Center of Advanced Study in Marine Biology, Annamalai University, Parangipettai, TN, India.
Satishkumar RamrajDepartment of Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Kathiresan KandasamyDepartment of Marine Sciences, Center of Advanced Study in Marine Biology, Annamalai University, Parangipettai, TN, India.
Somasundaram S ThirugnanasambandanDepartment of Marine Sciences, Center of Advanced Study in Marine Biology, Annamalai University, Parangipettai, TN, India.
Dinesh Babu SomasundaramDepartment of Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Terence S HermanStephenson Cancer Center, Oklahoma City, OK, USA.
Natarajan AravindanDepartment of Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
University of Oklahoma Health Sciences Center · USAnnamalai University · INOklahoma State University Oklahoma City · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapy-resistant pancreatic cancer (PC) cells play a crucial role in tumor relapse, recurrence, and metastasis. Recently, we showed the anti-PC potential of an array of seaweed polyphenols and identified efficient drug deliverables. Herein, we investigated the benefit of one such deliverable, Hormophysa triquerta polyphenol (HT-EA), in regulating the dissemination physiognomy of therapy-resistant PC cells in vitro,and residual PC in vivo. Human PC cells exposed to ionizing radiation (IR), with/without HT-EA pre-treatment were examined for the alterations in the tumor invasion/metastasis (TIM) transcriptome (93 genes, QPCR-profiling). Utilizing a mouse model of residual PC, we investigated the benefit of HT-EA in the translation regulation of crucial TIM targets (TMA-IHC). Radiation activated 30, 50, 15, and 38 TIM molecules in surviving Panc-1, Panc-3.27, BxPC3, and MiaPaCa-2 cells. Of these, 15, 44, 12, and 26 molecules were suppressed with HT-EA pre-treatment. CXCR4 and COX2 exhibited cell-line-independent increases after IR, and was completely suppressed with HT-EA, across all PC cells. HT-EA treatment resulted in translational repression of IR-induced CXCR4, COX2, β-catenin, MMP9, Ki-67, BAPX, PhPT-1, MEGF10, and GRB10 in residual PC. Muting CXCR4 or COX2 regulated the migration/invasion potential of IR-surviving cells, while forced expression of CXCR4 or COX2 significantly increased migration/invasion capabilities of PC cells. Further, treatment with HT-EA significantly inhibited IR-induced and CXCR4/COX2 forced expression-induced PC cell migration/invasion. This study (i) documents the TIM blueprint in therapy-resistant PC cells, (ii) defines the role of CXCR4 and COX2 in induced metastatic potential, and (iii) recognizes the potential of HT-EA in deterring the CXCR4/COX2-dependent dissemination destiny of therapy-resistant residual PC cells.

Indexed as

AnimalsCell Line, TumorCell MovementCyclooxygenase 2Down-RegulationDrug Resistance, NeoplasmGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMiceNeoplasm InvasivenessNeoplasm, ResidualPancreatic NeoplasmsPhaeophyceaePlant ExtractsPolyphenolsCXCR4 protein, humanCyclooxygenase 2Plant ExtractsPolyphenolsPTGS2 protein, humanReceptors, CXCR4pancreatic cancerresidual pancreatic cancerseaweed polyphenolstumor invasion and metastasistumor relapse and recurrence

Identifiers

PMID27974694
PMCPMC5351584
OpenAlexW2565108650

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.